Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Jones

Showing results (261-270 of 363) with videos related to

Pageof 37
Sort By:
Brain : a Journal of Neurology|July 5, 2022
Neurovascular injury with complement activation and inflammation in COVID-19Myoung Hwa Lee, Daniel P Perl, Joseph Steiner, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 28, 2006
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimusGary Levy, Gian Luca Grazi, Fernando Sanjuan, et al.
Health Technology Assessment (Winchester, England)|September 29, 2018
Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCTAndrew Jahoda, Richard Hastings, Chris Hatton, et al.
The Lancet. Oncology|September 5, 2022
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trialFred Saad, Antoine Thiery-Vuillemin, Pawel Wiechno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Open Heart|July 2, 2020
Research priorities in advanced heart failure: James Lind alliance priority setting partnershipClare J Taylor, Alyson L Huntley, John Burden, et al.
Urologic Oncology|July 18, 2024
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxelFrancesca Jackson-Spence, Charlotte Ackerman, Robert Jones, et al.
JNCI Cancer Spectrum|November 23, 2024
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trialHeinz-Josef Lenz, Tianshu Liu, Emerson Y Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2014
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancerThomas Powles, Shah-Jalal Sarker Foreshew, Jonathan Shamash, et al.
Pageof 37

Showing results (261-270 of 363) with videos related to

Sort By:
Pageof 37
Brain : a Journal of Neurology|July 5, 2022
Neurovascular injury with complement activation and inflammation in COVID-19Myoung Hwa Lee, Daniel P Perl, Joseph Steiner, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 28, 2006
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimusGary Levy, Gian Luca Grazi, Fernando Sanjuan, et al.
Health Technology Assessment (Winchester, England)|September 29, 2018
Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCTAndrew Jahoda, Richard Hastings, Chris Hatton, et al.
The Lancet. Oncology|September 5, 2022
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trialFred Saad, Antoine Thiery-Vuillemin, Pawel Wiechno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Open Heart|July 2, 2020
Research priorities in advanced heart failure: James Lind alliance priority setting partnershipClare J Taylor, Alyson L Huntley, John Burden, et al.
Urologic Oncology|July 18, 2024
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxelFrancesca Jackson-Spence, Charlotte Ackerman, Robert Jones, et al.
JNCI Cancer Spectrum|November 23, 2024
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trialHeinz-Josef Lenz, Tianshu Liu, Emerson Y Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2014
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancerThomas Powles, Shah-Jalal Sarker Foreshew, Jonathan Shamash, et al.
Pageof 37